New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
12:51 EDTINSMInsmed price target raised to $30 from $25 at H.C. Wainwright
H.C. Wainwright raised its price target for Insmed shares to $30 following the company's Phase II data for Arikayce and keeps a Buy rating on the stock. The firm believes uncertainty over the drug's clinical meaningfulness has been removed with the data.
News For INSM From The Last 14 Days
Check below for free stories on INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INSM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use